Alivus Life Sciences · NSE: ALIVUS · BSE: 543322
Q2 FY25 results · Jul–Sep 2024
Alivus Life Sciences reported revenue from operations of ₹506.88 crore (down 14.9% from Q2 FY24) and net profit of ₹95.32 crore (down 19.7% from Q2 FY24) for Q2 FY25 (Jul–Sep 2024), on a standalone basis.
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 506.88 | 595.36 | −14.9% | 588.62 | −13.9% |
| Other income | 8.53 | 5.37 | +58.9% | 5.49 | +55.3% |
| Total income | 515.41 | 600.73 | −14.2% | 594.11 | −13.2% |
| Profit before tax | 127.46 | 158.93 | −19.8% | 150.24 | −15.2% |
| Net profit for the period | 95.32 | 118.74 | −19.7% | 111.48 | −14.5% |
| EPS, basic (₹) | 7.78 | 9.69 | −19.7% | 9.10 | −14.5% |
| Net margin (%) | 18.8 | 19.9 | 18.9 |
Standalone
- Filed with BSE
- 25 Oct 2024, 14:51 IST
- Board meeting
- 24 Oct 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE